Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03110900 · ClinicalTrials.gov registry record · Phase 4
Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation
A Phase 4 study, sponsored by University of Arkansas.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT03110900 is a Phase 4 study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 2 participants.
The verdict
NCT03110900, a Phase 4 study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the noninferiority of inhaled loxapine compared to intramuscular haloperidol/lorazepam on agitation reduction at 120 minutes.
Interventions
- DRUG Haloperidol + lorazepam
- DRUG Loxapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-09-30 |
| Est. Completion | 2018-04-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03110900
The ClinicalTrials.gov registry entry for NCT03110900 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Haloperidol + lorazepam is the first listed.
NCT03110900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03110900 about?
NCT03110900 is a clinical study titled "Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation". The primary objective of this study is to determine the noninferiority of inhaled loxapine compared to intramuscular haloperidol/lorazepam on agitation reduction at 120 minutes.
What is the current status of trial NCT03110900?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2017-09-30. Estimated completion is 2018-04-04.
What interventions are being tested in trial NCT03110900?
The interventions under investigation include: Haloperidol + lorazepam (DRUG), Loxapine (DRUG).
Who is sponsoring clinical trial NCT03110900?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.